“…For infliximab, this finding has been demonstrated in studies on rheumatoid arthritis and ankylosing spondylitis with the joint use of methotrexate [52][53][54]. It has also been demonstrated in inflammatory bowel disease with thiopurine drugs and methotrexate [9,18,35,50,[55][56][57], with no differences among them [50], with the frequency of aTNF-ab at 18% without Immunosuppressives and 10% with Immunosuppressives (p=0.02) [18,24,42].…”